Company profile: Amgen
1.1 - Company Overview
Company description
- Provider of biotechnology-based human therapeutics, including biosimilar medicines for oncology, hematology, and chronic inflammatory diseases, and oncology therapies spanning precision oncology and targeted immunotherapy. Also offers the Amgen Biotech Experience for hands-on secondary school education and supports science education and communities through the Amgen Foundation.
Products and services
- Oncology Therapeutics: Amgen engineers precision-engineered cancer-targeting therapies that leverage precision oncology and targeted immunotherapy approaches for more directed treatment of malignancies
- Biosimilars: Amgen produces biologic-class biosimilar medicines highly similar to reference biologic drugs, focusing on oncology, hematology, and chronic inflammatory diseases across multiple therapeutic areas
- Amgen Biotech Experience: Amgen delivers global-scale hands-on biotechnology education to secondary school students, offering professional-grade scientific equipment and training
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Amgen
InnoPharma
HQ: United States
Website
- Description: Provider of niche-generic, specialty pharmaceutical and bio-pharmaceutical product development, operating as a privately held pharmaceutical R&D company founded in 2005 and based in Piscataway, New Jersey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InnoPharma company profile →
Santarus
HQ: United States
Website
- Description: Provider of specialty biopharmaceutical products focused on acquiring, developing and commercializing proprietary therapies that address the needs of patients treated by physician specialists; current commercial efforts encompass five products, including UCERIS (budesonide) extended release tablets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Santarus company profile →
Q BioMed
HQ: United States
Website
- Description: Provider of radiopharmaceutical and therapeutic candidates, including Strontium-89 Chloride Injection for relief of bone pain from skeletal metastases; Uttroside-B, a chemotherapeutic agent under development for liver cancer; QBM-001, a preclinical candidate targeting pediatric minimally verbal autism spectrum disorder; and MAN-01, a preclinical topical eyedrop for glaucoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Q BioMed company profile →
Ascendis Pharma
HQ: United States
Website
- Description: Provider of the TransCon prodrug technology platform, which transiently conjugates an inert carrier to a parent drug for systemic or localized release, and a pipeline of investigational therapies: TransCon hGH for growth hormone deficiency, TransCon PTH for hypoparathyroidism, TransCon CNP for achondroplasia, and oncology candidates TransCon TLR7/8 Agonist and TransCon IL-2 β/γ.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ascendis Pharma company profile →
Recordati
HQ: Italy
Website
- Description: Provider of medications and treatment options across specialty and primary care, consumer healthcare, and rare diseases, focusing on the development and distribution of therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Recordati company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Amgen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Amgen
2.2 - Growth funds investing in similar companies to Amgen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Amgen
4.2 - Public trading comparable groups for Amgen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →